Showing 281 - 285 results of 285 for search '"Immunomodulation"', query time: 0.03s Refine Results
  1. 281

    A Study of Molecular Mimicry and Immunological Cross-reactivity between Hepatitis B Surface Antigen and Myelin Mimics by Dimitrios-Petrou Bogdanos, Heather Smith, Yun Ma, Harold Baum, Giorgina Mieli-Vergani, Diego Vergani

    Published 2005-01-01
    “…In view of the observed SHBsAg/MOG cross-reactivity, the vaccine's possible role as an immunomodulator of viral/self cross-reactivity must be further investigated.…”
    Get full text
    Article
  2. 282

    Application of N-Acetyl-Glucosaminil-N-Acetyl-Muramyl Dipeptide during Triple Component Anti-Helicobacter Pylori Therapy in the Period of Coronavirus Infection COVID-19 by M. R. Konorev, E. N. Tyshevich, R. A. Pavlyukov

    Published 2023-08-01
    “…In H. pylori-infected patients, GMDP (an immunomodulator based on L. bulgaricus) at a dose of 1-10 mg/day, during a 10-day triple eradication therapy, allows a significant (p < 0.05) increase in the frequency of H. pylori eradication and reduce the incidence of adverse reactions compared with a 10-day protocol without adjuvant therapy with GMDP. …”
    Get full text
    Article
  3. 283

    Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination by Zachary S Morris, Paul M Sondel, Amy K Erbe, Alexander L Rakhmilevich, Amber M Bates, Peter M Carlson, Alexander A Pieper, Ravi B Patel, Jen Birstler, Joseph Grudzinski, Reinier Hernandez, Bryan P Bednarz, Jamey P Weichert, Arika S Feils, Matthew Rodriquez, Claire Sun, Ian Marsh

    Published 2023-01-01
    “…Using flow cytometry, we identified an influx of CD8+ T cells with a less exhausted phenotype in both the ISV-targeted primary and the distant secondary tumor following the combination of secondary tumor EBRT or TRT with primary tumor ISV.Conclusions We report a novel use for low-dose RT, not as a direct antitumor modality but as an immunomodulator capable of driving and expanding antitumor immunity against metastatic tumor sites following ISV.…”
    Get full text
    Article
  4. 284

    4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models by Ignacio Melero, Alvaro Teijeira, Christian Klein, Maria E Rodriguez-Ruiz, Christina Claus, Pablo Umana, Tamara Tanos, Carlos E De Andrea, Carlos Luri-Rey, Paloma Sanchez-Mateos, Leticia Fernández-Rubio, María Collantes, Irantzu Serrano-Mendioroz, Celia Barrio-Alonso, Antonio Rullan, Jon Ander Simon, Eneko Garate-Soraluze, Claudia del Pilar Herrero

    Published 2025-02-01
    “…We hypothesized that IR increases FAP expression in CAFs, therefore the combination of IR with targeted immunomodulators such as an agonistic anti-FAP-4-1BBL fusion protein could enhance the immune-mediated antitumoral effects of these treatments.Methods The murine transplantable TS/A tumor-cell-line co-engrafted with CAFs was used to investigate increases in FAP expression in tumors following irradiation using immunohistochemistry, real-time polymerase chain reaction (RT-PCR) and multiplex tissue immunofluorescence. …”
    Get full text
    Article
  5. 285

    Immune Modulation Effect of Administration of Rice Bran Extract with Increased Solubility Fermented by <i>Lentinus edodes</i> UBC-V88 in Cyclophosphamide-Treated Mice Model by Gi-Jung Kim, Yelim Jang, Ji-Yoon Hong, Kyoung-Tae Kwon, Dae-Weon Kim, Dae-Jung Kang, Sung-Joo Hwang, Jung-Yun Lee, Emmanouil Apostolidis, Young-In Kwon

    Published 2025-01-01
    “…The changes in the weight of the thymus and the spleen, immunoglobulins, and cytokine expressions were measured as biomarkers of immunomodulating potential after 14 days of oral administration of FRB and RB (0.5 g/kg-body weight (b.w.), respectively). …”
    Get full text
    Article